However, a recent study evaluated neuronal pentraxin as a synaptic-dysfunction marker and reported a decrement in the neuronal pentraxin-2 (NPTX2) in GRN and C9ORF72 mutation carriers but not in MAPT mutation carriers [234] In conclusion, it is clear from these studies that multiple biomarker panels will presumably be necessary to explore the specific pathogenesis of ALS/FTD and to provide a personalized approach to outcome measures in trials. The gene discussed is NPTX2; the disease is amyotrophic lateral sclerosis.